echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Qiangbin Wang Research Group of Suzhou Institute of Nanotechnology, Chinese Academy of Sciences AM: Nanomedicine-mediated stem cell therapy for Alzheimer’s disease

    Qiangbin Wang Research Group of Suzhou Institute of Nanotechnology, Chinese Academy of Sciences AM: Nanomedicine-mediated stem cell therapy for Alzheimer’s disease

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Innovation point: Alzheimer's disease (AD) is a complex disease with multiple pathological features.

    Wang Qiangbin's research team from the Suzhou Institute of Nanotechnology, Chinese Academy of Sciences has developed a multifunctional neural stem cell (NSC) treatment strategy that combines genes, nanomedicine and stem cells to achieve continuous Aβ clearance and promote nerve regeneration and repair in a mouse model, showing good improvements The efficacy of memory and cognition in AD mice.

    Keywords: Suzhou Institute of Nanotechnology and Nano-Bionics, Chinese Academy of Sciences, Aβ degradation, nerve regeneration and repair, nanopharmaceuticals, Alzheimer's disease Alzheimer's disease (AD) is a common dementia, and currently there is no cure However, the existing treatment methods, such as the commonly used drug treatment of brain amyloid (Aβ), can only moderately alleviate the symptoms of AD and slow down its pathological progress.

    AD is a neurodegenerative disease with complex and multi-pathological features.
    How to simultaneously achieve the treatment of pathological symptoms such as Aβ deposition and at the same time achieve nerve regeneration to improve cognitive impairment is the main challenge facing AD treatment.

    In response to this challenge, the team of researcher Wang Qiangbin from the Suzhou Institute of Nanotechnology and Nanobionics, Chinese Academy of Sciences designed a multifunctional neural stem cell (NSC) treatment strategy that combines genes, drugs and stem cells, which can be implemented in a mouse model at the same time Aβ clears and promotes nerve regeneration and repair, and shows a good effect on improving the memory and cognition of AD mice (Figure 1).

    First, the experiment developed a genetically engineered NSCs (NEP-NSCs) that can stably and continuously express enkephalinase (NEP), which can release NEP to achieve efficient and sustained degradation of Aβ in the brain microenvironment, and maintain Aβ Metabolism is balanced, while promoting the survival of NSCs; on this basis, in order to overcome the adverse reactions related to the pathological microenvironment of AD and promote the neuronal differentiation of NEP-NSCs, a PBAE with high gene/drug delivery efficiency was constructed experimentally.
    PLGA-Ag2S-RA-siSOX9 (PPAR-siSOX9) nano-pharmaceuticals, which can promote the differentiation of NEP-NSCs into neurons by synergistically regulating Wnt/β-catenin and RA signaling pathways and inhibit their glial differentiation; also based on Ag2S The near-infrared Ⅱ zone fluorescence of quantum dots can also realize real-time imaging guidance for NEP-NSCs transplantation, and realize accurate transplantation of NEP-NSCs in the hippocampus.

    Benefiting from the multiple advantages of long-term degradation of Aβ, nerve regeneration and repair, and precise cell transplantation, this strategy has shown good short-term and long-term AD effects.
    After a single treatment for 1 month and 6 months later, the water maze behavior of AD mice The analysis showed good memory and cognitive improvement (Figure 3).

    The development of this technology provides a new idea for the development and application of multifunctional stem cell therapies that can treat a variety of AD diseases.

    Related work was published on Advanced Materials.

    The above-mentioned research work has been awarded the National Natural Science Foundation of China's key and general projects (21934007, 21778070), the Chinese Academy of Sciences Basic Frontier Scientific Research Program from 0 to 1 Original Innovation Project (ZDBS-LY-SLH021), the National Key Research and Development Program (2016YFA0101503), etc.
    Funding.WILEY paper information: A nanoformulation-mediated multifunctional stem cell therapy with improved beta-amyloid clearance and neural regeneration for Alzheimer's disease.
    Dehua Huang, Yuheng Cao, Xue Yang, Yongyang Liu, Yejun Zhang, Chunyan Li, Guangcun Chen*, Qiangbin Wang* Advanced MaterialsDOI: 10.
    1002/adma.
    202006357.
    Click "Read the original text" in the lower left corner to view the original text of the paper.

    About Advanced Materials Journal "Advanced Materials" (Advanced Materials) is a well-known authoritative journal in materials science published by Wiley with a history of more than 30 years.

    The journal focuses on the frontier development of functional materials in various fields such as chemistry, physics, biology and related interdisciplinary subjects, and has a wide range of influence.

    The latest impact factor is 27.
    389, and the 2020 SCI journals of the Chinese Academy of Sciences will be divided into the Q1 area of ​​the material science category and the Q1 area of ​​the engineering technology category.

    Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
    Follow us to share cutting-edge information|Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
    com
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.